Our Pricing

Get Your Online Prescription UK - Licensed Doctors

Published on: June 03, 2026

Accessing an online prescription UK weight loss treatment has never been more straightforward. At Cured Pharmacy, our UK-registered clinical team provides free consultations in under 3 minutes, prescribing genuine MHRA-licensed medications including Mounjaro, Wegovy, and Saxenda with complete discretion and transparent pricing from £135.00.

How Online Prescription Weight Loss Services Work in the UK

The online prescription UK weight loss process at Cured Pharmacy follows strict GPhC and MHRA regulations to ensure patient safety. You complete a comprehensive clinical assessment reviewed by a UK-registered prescriber who evaluates your medical history, current medications, and suitability for prescription weight loss treatments. This isn't a tick-box exercise — our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), assesses each consultation individually to determine the most appropriate treatment option.

Once approved, your prescription is dispensed from our UK-registered pharmacy (GPhC 9012511) and delivered in 100% discreet packaging. All medications are genuine UK-licensed products sourced directly from licensed wholesalers, never grey-market imports. The entire process typically completes within 24-48 hours from consultation to delivery, subject to prescriber approval and stock availability.

GLP-1 Receptor Agonist Injections: The Gold Standard for Weight Loss

GLP-1 receptor agonists represent the most effective prescription weight loss treatments currently licensed in the UK. These medications work by mimicking glucagon-like peptide-1, a natural hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity. Clinical trials have demonstrated substantially greater weight reduction compared to older treatments like orlistat [1].

Tirzepatide (Mounjaro) is the first dual GIP/GLP-1 receptor agonist, activating two complementary pathways rather than one. In the SURMOUNT-1 trial, participants achieved an average body weight reduction of 20.9% over 72 weeks on the 15mg dose — the highest efficacy seen in any obesity medication trial to date [1]. Semaglutide (Wegovy) produced average weight loss of 14.9% in the STEP-1 trial, while liraglutide (Saxenda) achieved 8.4% in the SCALE trial [2][3].

These aren't cosmetic treatments — NICE guidelines recommend GLP-1 medications for individuals with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes or hypertension. Your UK prescriber will assess your eligibility during the online consultation and recommend the most clinically appropriate option based on your individual circumstances.

Choosing Between Mounjaro, Wegovy, and Saxenda

Mounjaro offers the highest average weight reduction but requires once-weekly subcutaneous injection and costs from £135.00 per month. Wegovy provides substantial efficacy with once-weekly dosing from £135.00, while Saxenda requires daily injection but starts from £135.00, making it the most accessible GLP-1 option. Your prescriber will consider efficacy data, injection frequency preference, budget, and medical history when recommending treatment.

Orlistat: Prescription and Over-the-Counter Options

Orlistat works through a completely different mechanism than GLP-1 treatments — it inhibits pancreatic and gastric lipases, reducing dietary fat absorption by approximately 30% [4]. The prescription-strength 120mg dose (Xenical, generic orlistat) requires a clinical assessment, while the 60mg dose (Alli, Orlos) is available for purchase without prescription for individuals meeting specific BMI criteria.

Clinical trials show orlistat 120mg produces average weight loss of 5-10% when combined with a reduced-calorie diet, significantly lower than GLP-1 medications but still clinically meaningful [4]. The main consideration with orlistat is gastrointestinal side effects — unabsorbed fat passes through the digestive system, causing oily stools, flatulence, and faecal urgency, particularly when consuming high-fat meals.

Orlistat suits patients who prefer oral medication over injections, have contraindications to GLP-1 treatments, or want a lower-cost option. Prescription orlistat 120mg starts from £135.00, while over-the-counter Orlos 60mg begins at £135.00. All orlistat products require adherence to a reduced-fat diet (≤30% of calories from fat) to minimise side effects and optimise efficacy.

Orlistat vs GLP-1 Injections: Which Delivers Better Results?

Head-to-head trials consistently show GLP-1 receptor agonists produce two to three times greater weight reduction than orlistat, though orlistat remains a valid option for patients unsuitable for injectable treatments [1][4]. The choice depends on individual medical history, tolerance for injections, budget considerations, and willingness to manage potential gastrointestinal effects with orlistat or injection-site reactions with GLP-1s.

What to Expect During Your Online Consultation

The clinical assessment takes under 3 minutes to complete but covers comprehensive medical ground. You'll answer questions about your current weight and height, previous weight loss attempts, existing medical conditions (particularly cardiovascular disease, pancreatitis, thyroid disorders, and diabetic retinopathy), current medications, and family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — both contraindications for GLP-1 treatments.

Our UK prescribers review every consultation individually. If approved, you'll receive a prescription for the clinically appropriate dose and strength. If the prescriber identifies any safety concerns or contraindications, they'll decline the consultation and may suggest alternative options or recommend you consult your NHS GP for further evaluation. This rigorous process ensures patient safety remains paramount — we never compromise clinical standards for commercial convenience.

Pricing is transparent before you start the consultation. You'll see the exact cost of your prescribed treatment upfront, with no hidden fees or surprise charges at checkout. Cured Pharmacy guarantees the lowest prices in the UK for prescription weight loss medications, and if you find a lower price elsewhere, we'll match it.

Safety Considerations and Side Effects

GLP-1 receptor agonists commonly cause gastrointestinal side effects during the initial titration period, including nausea, vomiting, diarrhoea, and constipation. These effects typically diminish over 4-8 weeks as your body adapts to the medication [2][3]. Starting at a low dose and gradually increasing reduces the severity of these symptoms — this is why Mounjaro begins at 2.5mg, Wegovy at 0.25mg, and Saxenda at 0.6mg.

Rare but serious adverse effects include pancreatitis (characterised by severe, persistent abdominal pain radiating to the back), gallbladder disease, hypoglycaemia when used with insulin or sulfonylureas, and diabetic retinopathy complications in patients with pre-existing retinopathy [1][2]. GLP-1 medications carry a boxed warning about thyroid C-cell tumours observed in rodent studies, though no causal relationship has been established in humans. These treatments are contraindicated if you have a personal or family history of medullary thyroid carcinoma.

Orlistat's side effects are predominantly gastrointestinal and directly related to its mechanism of action — preventing fat absorption leads to oily spotting, flatulence with discharge, faecal urgency, and increased defecation frequency [4]. These effects are manageable by adhering strictly to a low-fat diet but can be socially disruptive if dietary fat intake isn't controlled.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, visual changes, signs of pancreatitis, persistent vomiting preventing fluid intake, or symptoms of gallbladder disease (pain in the upper right abdomen, fever, jaundice). For non-urgent concerns about side effects or treatment response, contact our clinical team on (+44) 116 4646009 or through your patient account.

Maximising Results: Medication Alongside Lifestyle Modification

Prescription weight loss medications are most effective when combined with dietary modification and increased physical activity. Clinical trials demonstrating the impressive efficacy of GLP-1 treatments included lifestyle intervention components — participants followed reduced-calorie diets and exercise programmes alongside medication [1][2]. The medication facilitates adherence to these lifestyle changes by reducing appetite and food cravings.

A structured approach optimises outcomes: aim for a 500-750 calorie daily deficit through diet, incorporate 150-300 minutes of moderate-intensity aerobic activity weekly, and include resistance training twice weekly to preserve lean muscle mass during weight loss. GLP-1 medications make this far more achievable by fundamentally altering appetite signalling — patients consistently report feeling satisfied with smaller portions and experiencing fewer cravings between meals.

Long-term weight maintenance requires ongoing treatment in most cases. Clinical trials show that discontinuing GLP-1 medications typically results in weight regain, as the underlying biological drivers of obesity reassert themselves [5]. This isn't treatment failure — it reflects the chronic nature of obesity as a disease. Your prescriber will discuss maintenance strategies during follow-up consultations, which may include continuing medication at a maintenance dose, transitioning between treatments based on response and tolerability, or exploring other options if weight loss plateaus.

Monitoring Progress and Adjusting Treatment

Regular monitoring helps optimise treatment response. Track your weight weekly at the same time of day, monitor waist circumference monthly, and note any side effects or concerns. Your prescriber may adjust your dose based on weight loss progress, tolerability, and individual response. Most patients require 3-6 months to reach their target maintenance dose, with maximum weight loss typically occurring within 12-18 months of starting treatment.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to treatment, dietary modification, and physical activity levels.